EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Clascoterone 1% in the Treatment of Acne: A Review of its Efficacy, Safety, and Therapeutic Positioning

P Balado-Simó, M Brufau-Cochs, D Morgado-Carrasco

Actas Dermo-Sifiliográficas · 2026-04 · 117 (4) · 104587

DOI: 10.1016/j.ad.2025.104587 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Actas Dermo-Sifiliográficas, 2026-04. Verfasst von P Balado-Simó und 2 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Acne Vulgaris, Cortodoxone, Androgen Antagonists, Dermatologic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Topical clascoterone (TC) is the first topical antiandrogen approved by the Food and Drug Administration (FDA) for the treatment of acne and recently approved in Europe. Through bibliographic searches in Medline and Google Scholar, we conducted a narrative review to assess the usefulness of TC in acne management. Several randomized clinical trials have demonstrated its efficacy and safety (with virtually no systemic adverse effects), but few have compared its effectiveness with other topical agents or its use in combination. It is a highly interesting therapeutic alternative, particularly for patients who do not tolerate other topical treatments or in cases of acne with a strong hormonal component. U.S. treatment guidelines conditionally recommend it for acne management due to its high cost. The strength of recommendation is lower than that of topical retinoids and benzoyl peroxide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acne VulgarisCortodoxoneAndrogen AntagonistsDermatologic AgentsHumansRandomized Controlled Trials as TopicTreatment OutcomePropionates

Stichwörter der Autor:innen

AcneAntiandrogenic therapyClascoteroneSpironolactoneTopical treatment

Substanzen

ClascoteroneCortodoxoneAndrogen AntagonistsDermatologic AgentsPropionates

Autor:innen und Institutionen

  • Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
  • Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain; Servicio de Dermatología, Hospital de Figueres, Fundació Salut Empordà, Figueres, Girona, Spain. Electronic address: mo…

Zitieren

APA

Balado-Simó, P., Brufau-Cochs, M., & Morgado-Carrasco, D. (2026). Clascoterone 1% in the Treatment of Acne: A Review of its Efficacy, Safety, and Therapeutic Positioning. Actas Dermo-Sifiliográficas, 117(4), 104587. https://doi.org/10.1016/j.ad.2025.104587

Vancouver

Balado-Simó P, Brufau-Cochs M, Morgado-Carrasco D. Clascoterone 1% in the Treatment of Acne: A Review of its Efficacy, Safety, and Therapeutic Positioning. Actas Dermo-Sifiliográficas. 2026;117(4):104587. doi:10.1016/j.ad.2025.104587

BibTeX
@article{BaladoSim2026,
  author = {Balado-Simó, P and Brufau-Cochs, M and Morgado-Carrasco, D},
  title = {Clascoterone 1% in the Treatment of Acne: A Review of its Efficacy, Safety, and Therapeutic Positioning},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2026},
  volume = {117},
  number = {4},
  pages = {104587},
  doi = {10.1016/j.ad.2025.104587}
}
Kostenlos starten →